This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Forsbeck, K. Articles by Ingelman-Sundberg, M. Search for Related Content PubMed PubMed Citation Articles by Forsbeck, K. Articles by Ingelman-Sundberg, M.

Phorbol Ester-induced Alteration of Differentiation and Proliferation in Human Hematopoietic Tumor Cell Lines: Relationship to the Presence and Subcellular Distribution of Protein Kinase C¹

Department of Pathology, Uppsala University Hospital, S-751 85 Uppsala [K. F., K. N.], and Department of Physiological Chemistry, Karolinska Institute, S-104 01 Stockholm [A. H., G. S., M. I-S.], Sweden

The intracellular translocation of protein kinase C (PKC) from the soluble to the membranous fraction has been shown previously to correlate with biological activity of phorbol esters in several systems. In this paper, we describe that PKC translocation was a general phenomenon in all PKC containing cell types when five 12-O-tetradecanoylphorbol-13-acetate (TPA) responsive and nonresponsive hematopoietic tumor cell lines were investigated. The nonresponsive cell line U-266 contained undetectable levels of PKC. The dose of TPA required for translocation was similar to the TPA concentration necessary to suppress erythroid differentiation in K-562 cells and to induce macrophage differentiation in U-937 cells, but 100-fold higher than that required for suppression of proliferation in K-562 and U-937 cells. By contrast, PKC translocation and TPA induced proliferation inhibition exhibited a similar dose dependence in a subline of U-937 (U-937 RES) adapted to growth in the presence of 10^-9 M TPA. It is suggested that U-937 RES is deficient in a TPA dependent but PKC independent signal pathway.

¹ Supported by grants from the OE and Edla Johansson Foundation, the Magnus Bergwall Foundation, the Swedish Cancer Society, and the Swedish Medical Research Council.

² To whom requests for reprints should be addressed.

Received 2/26/85. Revised 8/26/85. Accepted 8/27/85.